Herd immunity with new COVID variants?

  • Thread starter Thread starter ElliotSmith
  • Start date Start date
  • Tags Tags
    Covid
AI Thread Summary
Survivors of the original COVID-19 strain may have some immunity to new variants, but the effectiveness of their antibodies can vary. Natural infection generates a diverse range of antibodies targeting multiple viral proteins, while vaccines produce antibodies focused on a specific part of the virus crucial for cell entry. Although antibodies from natural infections may not be uniformly effective against new variants, T cell responses remain robust and largely unaffected by these variants. This T cell immunity is significant in providing protection against severe disease, even as the ability of vaccines to prevent infection diminishes. Recent studies highlight the importance of targeting specific viral epitopes for developing effective therapies against current and future strains of SARS-CoV-2.
ElliotSmith
Messages
167
Reaction score
104
TL;DR Summary
Do natural COVID antibodies protect against the new variants?
If someone has had the original COVID-19 strain and survived, does this mean that they have any immunity to the new variants? Or do the new variants completely ignore any antibodies that someone who survived the original virus has?
 
Biology news on Phys.org
The difference between the antibodies you get from an invection vs. antibodies you might get from the new immunizations they are now producing, is that the immunizations produce antibodies to only a single part of the virus, a part deeply involed involved in infecting cells. If the antibody binding this site (epitope) doesn't directly lead to the virus's destruction, it will physically block the virus's ability to a gain entry to a cells to infect.
Antibodies acquired by being infected can be from any exposed molecular surface of the viruses (several proteins, with many different places an antibody could bind).
Antibodies, to parts of the virus's surface not targeted in the immunizations, can act as signals to immune cells to remove the virus, but until that happens, the virus is still infective.

Summary:
The antibodies from a natural infection, will raise a lot of different antibodies.
The antibodies raised by the immunization will be a sub-set of those raised by an infection, but they will be very effective.
Not all of the antibodies from a natural infection will be equally effective in fighting new challenges.
 
Last edited:
  • Like
Likes atyy and ElliotSmith
An important thing to keep in mind is that even if antibodies protect less against new variants, the T cells protection developed by natural infection or by Pfizer vaccines has been negligibly affected by variants. The T cell responses may help explain why the vaccines continue to provide good protection against severe disease, even though their ability to protect from infection has decreased.
https://doi.org/10.1016/j.xcrm.2021.100355
https://immunology.sciencemag.org/content/6/59/eabj1750
https://www.nature.com/articles/s41586-021-03681-2
 
  • Informative
  • Like
Likes bhobba and BillTre
Hi Friends,

I was affected by COVID wave 2, It drained my energy level as well myself confidence. I got headache pain, and cold, and sneezing heavily... And also I faced hair fall issues... And then I have started browsing the information related to COVID and how to overcome this... I was read the many websites and I have shared the websites here. If anyone seeking or getting benefits from this one reply me here...

https://reliefseeker.com/news/hair-loss-treatment-guide
 

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape​

Here we comprehensively characterize escape, breadth and potency across a panel of SARS-CoV-2 antibodies targeting the receptor-binding domain (RBD). Despite a trade-off between in vitro neutralization potency and breadth of sarbecovirus binding, we identify neutralizing antibodies with exceptional sarbecovirus breadth and a corresponding resistance to SARS-CoV-2 escape. One of these antibodies, S2H97, binds with high affinity across all sarbecovirus clades to a cryptic epitope and prophylactically protects hamsters from viral challenge. Antibodies that target the angiotensin-converting enzyme 2 (ACE2) receptor-binding motif (RBM) typically have poor breadth and are readily escaped by mutations despite high neutralization potency. Nevertheless, we also characterize a potent RBM antibody (S2E128) with breadth across sarbecoviruses related to SARS-CoV-2 and a high barrier to viral escape. These data highlight principles underlying variation in escape, breadth and potency among antibodies that target the RBD, and identify epitopes and features to prioritize for therapeutic development against the current and potential future pandemics.
https://www.nature.com/articles/s41586-021-03807-6
 
https://www.nhs.uk/mental-health/conditions/body-dysmorphia/ Most people have some mild apprehension about their body, such as one thinks their nose is too big, hair too straight or curvy. At the extreme, cases such as this, are difficult to completely understand. https://www.msn.com/en-ca/health/other/why-would-someone-want-to-amputate-healthy-limbs/ar-AA1MrQK7?ocid=msedgntp&cvid=68ce4014b1fe4953b0b4bd22ef471ab9&ei=78 they feel like they're an amputee in the body of a regular person "For...
Thread 'Did they discover another descendant of homo erectus?'
The study provides critical new insights into the African Humid Period, a time between 14,500 and 5,000 years ago when the Sahara desert was a green savanna, rich in water bodies that facilitated human habitation and the spread of pastoralism. Later aridification turned this region into the world's largest desert. Due to the extreme aridity of the region today, DNA preservation is poor, making this pioneering ancient DNA study all the more significant. Genomic analyses reveal that the...

Similar threads

Back
Top